The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISHL12 2022 | Current and future perspectives for prognostication and MRD in Hodgkin lymphoma
Sven Borchmann, MD, University of Cologne, Cologne, Germany, shares some insights into the importance of improving tools used for the prognosis and diagnosis of patients with Hodgkin lymphoma (HL). Dr Borchmann first highlights challenges in the treatment of patients with HL, and then goes on to explain the importance of individualizing treatment and using biological factors and measurable residual disease (MRD) to improve prognostication. This interview took place at The 12th International Symposium on Hodgkin Lymphoma (ISHL12), held in Cologne, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Ownership interest in and founder of Liqomics
